|

Effect of Hypoxia on FMISO PET to Response to Lu-177 PSMA Treatment

RECRUITINGN/ASponsored by Cigdem Soydal
Actively Recruiting
PhaseN/A
SponsorCigdem Soydal
Started2024-02-01
Est. completion2026-02-01
Eligibility
Age18 Years+
SexMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06433063

Summary

It is aimed to evaluate hypoxia before Lu-177 PSMA treatment in prostate cancer and to show its effect on treatment success with 18F-FMISO PET imaging, which allows in-vivo evaluation and quantification of tumor hypoxia, which is known to be one of the factors affecting radiotherapy resistance.

Eligibility

Age: 18 Years+Sex: MALEHealthy volunteers accepted
Inclusion Criteria:

* over 18 years old
* Patients diagnosed with prostate cancer who were referred to our clinic for Lu-177 PSMA treatment and were found suitable for treatment

Exclusion Criteria:

* Has a life expectancy of less than 3 months
* ECOG\>2
* contraindication for radionuclide treatment with Lu-177 PSMA

Conditions3

CancerHypoxiaProstatic Neoplasms

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.